anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In a pharmacokinetic study of sixteen subjects with hepatic impairment (15 mild, 1 moderate per Child- Pugh score), both AUC and Cmax were approximately double the values seen in the healthy control group. Based on the findings, cyclobenzaprine should be used with caution in subjects with mild hepatic impairment starting with the 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe hepatic insufficiency, the use of cyclobenzaprine in subjects with moderate to severe impairment is not recommended.  
No significant effect on plasma levels or bioavailability of cyclobenzaprine or aspirin was noted when single or multiple doses of the two drugs were administered concomitantly. Concomitant administration of cyclobenzaprine hydrochloride and naproxen or diflunisal was well tolerated with no reported unexpected adverse effects. However combination therapy of cyclobenzaprine hydrochloride with naproxen was associated with more side effects than therapy with naproxen alone, primarily in the form of drowsiness. No well-controlled studies have been performed to indicate that cyclobenzaprine hydrochloride enhances the clinical effect of aspirin or other analgesics, or whether analgesics enhance the clinical effect of cyclobenzaprine hydrochloride in acute musculoskeletal conditions.
PROBLEM TO BE SOLVED: To efficiently produce a high quality extract of guava leaves by subjecting guava leaves to extraction with water or a hydrophilic solvent, partially concentrating the extracted liq., removing a material slightly soluble in the extracting solvent and concentrating the partially concd. liq. again. SOLUTION: Guava leaves are subjected to extraction with water, a hydrophilic solvent or a mixture of them. The hydrophilic solvent is preferably prim. alcohol or lower ketone and is especially preferably methanol, ethanol, butanol or acetone. The extraction is preferably carried out with a mixed solvent consisting of water and such a hydrophilic solvent. The resultant extracted liq. is partially concd. under reduced pressure until the volume is reduced to 1-10%, preferably about 50-60% of the original volume at room temp. to 70 deg.C, preferably about 30-40 deg.C. A material slightly soluble in the extracting solvent is removed from the concd. liq. by sedimentation or extraction and the treated partially cond. liq. is properly concd. optionally under reduced pressure.
Participants will complete functional magnetic resonance imaging (fMRI) and self-report questionnaires at baseline and 16 weeks. Participant will receive an encrypted study iPad enabled with Lumen at baseline. They will complete 8 PST sessions beginning with 4 weekly and then 4 biweekly intervals (i.e., on weeks 1, 2, 3, 4, 6, 8, 10, 12) over 12 weeks on their assigned iPad. Participants will also complete naturalistic end-of-day assessments for 7 days every 2 weeks (on weeks 0, 2, 4, 6, 8, 10, 12, 16), that is, 8 time series. Additionally, participants will complete depressive and anxiety symptoms questionnaire and user experience surveys at all PST sessions.
Low motivation to exercise is one of the barriers to participation in cardiac rehabilitation. Fear of activity after a cardiac event is associated with low levels of physical activity. This study aimed to develop and validate a scale to measure fear of activity in patients with coronary artery disease. A scale for Fear of ACTivity in patients with CAD (Fact-CAD) was created through semi-structured focus group interviews with patients. Face and content validity of Fact-CAD was verified. The scale was applied to 250 patients who had myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within the last 12 months. Psychometric analysis included model fit, unidimensionality, reliability, local dependency, differential item functioning and external construct validity. Analyses were performed using the Rasch Analysis Model.
The invention relates to an ultrasound coupling medium for use in medical diagnostics, which consists of a structure gel containing a matrix from PVA, guar or a mixture thereof. The novel coupling medium is preferably semiliquid and can be extruded to an up to 1/10 mm thick film which withstands pressures of up to 30 kp without tearing. The medium adapts itself exactly to the surface of the skin without forming substantial air pockets. Even when the skin is covered with hair, the novel coupling medium does not form substantial air pockets between the medium and the transmitter or the skin. Already a few seconds after the novel medium has been removed from the skin, the skin no longer feels wet and the medium can be removed from skin and hair without leaving residues. The novel coupling medium will keep at least one year and meets the requirements with respect to induction of allergies or dermatitis.
The invention discloses a medicine composition for assisting in recovery after tumor radiotherapy and a preparation method thereof. The medicine composition for assisting in recovery after the tumor radiotherapy comprises Chinese herbal medicinal ingredients and Western medicine ingredients. The Chinese herbal medicinal ingredients comprise semen sesami nigrum, galericulate skullcap, oxystelma esculentum, Peperomia duclouxii C.DC, Guangxi Mayterus Hookeri Loes, Adinandra mellettii, Smilax scobinicaulis, the root of Actinidia arguta (Sieb.et Zucc.) Flarich.ex Miq., Ampelopsis Brevipedunculata Trautv, bamboo rat oil, Caragana jubata (Pall.) Poir., Caragana brevifolia, Lemmaphyllum microphyllum Presl var.obovatum (Harr.) C.Chr., the root of melastoma dodecandrum, cypress oil, Sabia schumanniana Diels var. Bicolor (L. chen) YF Wu, Limonium wrightii extract and rhizoma bletillae extract. The Western medicine ingredients comprise vitamin C, D-fraction and pidotimod. The medicine composition is applied according to indications based on the integrated Chinese and western medicine theory, achieves scientific matching, has the effects of removing toxicity for detumescence, promoting granulation and relieving pain, dispersing and removing stasis, relieving convulsion for calming endogenous wind, clearing and activating the channels and collaterals and resisting tumor transfer, has the significant treatment effect on recovery after the tumor radiotherapy, and is gentle in medicine effect, safe and free of side effects.
BACKGROUND: Amino acids (AAs) are one of the primary metabolic substrates for cardiac work. The correlation between AAs and both atrial fibrillation (AF) and aging has been documented. However, the relationship between AAs and age-related AF remains unclear.
METHODS: Initially, the plasma AA levels of persistent AF patients and control subjects were assessed, and the correlations between AA levels, age, and other clinical indicators were explored. Subsequently, the age-related AF mouse model was constructed and the untargeted myocardial metabolomics was conducted to detect the level of AAs and related metabolites. Additionally, the gut microbiota composition associated with age-related AF was detected by a 16S rDNA amplicon sequencing analysis on mouse fecal samples.
RESULTS: Higher circulation levels of lysine (Student's t-test, P = 0.001), tyrosine (P = 0.002), glutamic acid (P = 0.008), methionine (P = 0.008), and isoleucine (P = 0.014), while a lower level of glycine (P = 0.003) were observed in persistent AF patients. The feature AAs identified by machine learning algorithms were glutamic acid and methionine. The association between AAs and age differs between AF and control subjects. Distinct patterns of AA metabolic profiles were observed in the myocardial metabolites of aged AF mice. Aged AF mice had lower levels of Betaine, L-histidine, L-alanine, L-arginine, L-Pyroglutamic acid, and L-Citrulline compared with adult AF mice. Aged AF mice also presented a different gut microbiota pattern, and its functional prediction analysis showed AA metabolism alteration.
CONCLUSION: This study provided a comprehensive network of AA disturbances in age-related AF from multiple dimensions, including plasma, myocardium, and gut microbiota. Disturbances of AAs may serve as AF biomarkers, and restoring their homeostasis may have potential benefits for the management of age-related AF.
Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
The overall objective of this randomized controlled trial is to conduct a long-term evaluation of the effects of the Transcendental Meditation (TM) program compared to health education (HE) on secondary prevention of clinical events in African American men and women with coronary artery disease (CAD). Patients (N=201; mean age 59 yrs) were enrolled with documented CAD (i.e., coronary angiogram showing at least one artery with \> 50% stenosis). Patients were pretested at baseline and every 6-12 months for the duration of the study for incidence of clinical events, BP, BMI, medication usage, lifestyle behaviors, psychosocial stress factors and intervention compliance. Subjects were followed for a maximum of 9.2 years (mean 5.4 years). The investigators hypothesize that a selected stress reduction intervention, the TM program compared with a health education control may significantly reduce risk for death, myocardial infarction (MI) and stroke in African American men and women with CHD. If successful, the Transcendental Meditation program may be clinically useful in the secondary prevention of cardiovascular disease in a high-risk population.
The invention discloses lysozyme oral care health-care fluid and a preparation method thereof. The lysozyme oral care health-care fluid comprises 0.001-10% of lysozyme, 0.01-10% of tea polyphenol, 0.001-0.1 ppm of vitamin B12, 0.1-10% of freshener, 1-20% of sweetening agents, 0.1-6% of solubilizing agents, 0.01-0.6% of scented water and 43.4-98.77% of purified water. The 0.01-10% of lysozyme, 0.01-10% of tea polyphenol and 1-20% of sweetening agents are sequentially dissolved in a stainless steel container according to a proportion, slightly stirred and sufficiently and evenly mixed, so that fluid A is obtained through preparation; the 0.1-10% of freshener and 0.01-0.6% of scented water are sequentially dissolved in the 0.1-6% of solubilizing agents according to a proportion, slightly stirred and sufficiently and evenly mixed, so that fluid B is obtained through preparation. The fluid B is slowly poured into the fluid A and stirred slightly, and the 0.001-0.1 ppm of vitamin B12 is added and sufficiently and evenly mixed. The evenly mixed material is filtered, packaged and subjected to filling, so that the health-care fluid is obtained. The lysozyme oral care health-care fluid is obvious in effect, main functional components are natural extracts and do not contain alcohol, and the lysozyme oral care health-care fluid is mild in taste and capable of effectively improving the micro-ecological environment of the oral cavity without stimulating the oral mucosa while meeting the requirements for cleaning the oral cavity and freshening breath.
Genetic predisposition to oxidative stress (OS) may influence the risk of Painful Diabetic Peripheral Neuropathy (PDPN). This study employed a Mendelian Randomization (MR) approach to investigate the causal relationship between genetic predisposition to OS and PDPN. Genetic instruments associated with OS biomarkers were selected as exposures. Summary-level data on PDPN was obtained from the largest available genome-wide association study (GWAS). MR analyses were conducted using the inverse-variance weighted (IVW) method, with sensitivity analyses employing the MR-Egger, weighted median, and MR-PRESSO approaches. Genetic predisposition to increased glutathione S-transferase (GST) activity was associated with a reduced risk of PDPN (OR=0.66, 95%CI: 0.49-0.89, P=0.006). Higher ascorbate levels conferred a protective effect against PDPN (OR=0.83, 95%CI: 0.71-0.97, P=0.018). No significant association was observed between genetic predisposition to OS biomarkers and PDPN severity. Genetic predisposition to increased GST activity and higher ascorbate levels protect against the development of PDPN, suggesting a causal relationship.
A method of allowing a user to scan products and obtain product recommendations according to the user's personal biological/genetic data by providing a wearable user device. The method utilizes a cartridge and a desktop test control system into which the cartridge is inserted to test the user's personal biological/genetic data. First, a user account is created with a tablet or the like in communication with an account server. The account is associated with a cartridge ID read from the cartridge by the tablet. After the wearable user device is connected to the detection control system, the cartridge ID is also read by the wearable user device and communicated to the server via the detection control system. As such, the detection is allowed to be associated with the user account that has been created. The test control system sends the test results to the server, and the server generates analysis results by analyzing the test results. The analysis results are then downloaded to the wearable user device via the detection control system or via some other channel. A product code is also downloaded to the wearable user device and stored in association with the product code.
Renal fibrosis is the common final pathway of progressive renal diseases, in which the macrophages play an important role. ELISA was used to detect CD5 antigen-like (CD5L) in serum samples from end-stage renal disease (ESRD), as well as in mice serum with unilateral ureteral occlusion (UUO). Recombinant CD5L was injected into UUO mice to assess renal injury, fibrosis, and macrophage infiltration. The expression of CD5L was significantly upregulated in the serum of patients with ESRD and UUO mice. Histological analysis showed that rCD5L-treated UUO mice had more severe renal injury and fibrosis. Furthermore, rCD5L promoted the phenotypic transfer of monocytes from Ly6Chigh to LyC6low. RCD5L promoted TGF-β signaling pathway activation by promoting Smad2/3 phosphorylation. We used Co-IP to identify HSPA5 interact with CD5L on cell membrane could inhibit the formation of the Cripto/HSPA5 complex, and promote the activation of the TGF-β signaling pathway. The CD5L antibody could reduce the degree of renal fibrosis in UUO mice.
A niosome having a metalloporphyrin complex embedded therein comprising a cationized metalloporphyrin complex and a niosome-forming substance. The niosome having a metalloporphyrin complex embedded therein has an SOD activity, can interact with superoxide anionic radicals (O 2   − .) as a target, and can reduce these radicals without fail. The niosome having a metalloporphyrin complex embedded therein can reach cells in living bodies such as cancer cells due to properties of a niosome. Therefore, the niosome having a metalloporphyrin complex embedded therein can exhibit an excellent effect of treating cancer by reducing O2−. in cancer cells. In addition, since the effect is selective, the niosome can be used as a novel anticancer agent without side effects. Moreover, the niosome having a metalloporphyrin complex embedded therein can be retained in the blood while exhibiting a superior antioxidation effect. The niosome can thus protect living bodies from hindrance brought about by active oxygen species.
NSAIDs, including ketorolac tromethamine, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)   
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ketorolac tromethamine tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ketorolac tromethamine tablets and evaluate the patient immediately.
Parkinson's disease is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, including hallucinations. The use of antipsychotic medications is a common strategy to manage hallucinations associated with Parkinson's disease psychosis (PDP). However, careful consideration is necessary when selecting the most appropriate drug due to the potential risks associated with the available treatment options. Atypical antipsychotics (AAPs), such as Pimavanserin and Clozapine, have effectively controlled PDP symptoms. On the contrary, the support for utilizing quetiapine is not as substantial as other antipsychotics because research studies specifically investigating its application are still emerging and relatively recent. The broad mechanisms of action of AAPs, involving dopamine and serotonin receptors, provide improved outcomes and fewer side effects than typical antipsychotics. Conversely, other antipsychotics, including risperidone, olanzapine, aripiprazole, ziprasidone, and lurasidone, have been found to worsen motor symptoms and are generally not recommended for PDP. While AAPs offer favorable benefits, they are associated with specific adverse effects. Extrapyramidal symptoms, somnolence, hypotension, constipation, and cognitive impairment are commonly observed with AAP use. Clozapine, in particular, carries a risk of agranulocytosis, necessitating close monitoring of blood counts. Pimavanserin, a selective serotonin inverse agonist, avoids receptor-related side effects but has been linked to corrected QT (QTc) interval prolongation, while quetiapine has been reported to be associated with an increased risk of mortality. This review aims to analyze the benefits, risks, and mechanisms of action of antipsychotic medications to assist clinicians in making informed decisions and enhance patient care.
PURPOSE: To stably hold a micelle structure while stabilizing the endotioxin activity in a specimen and a standard product over a long period of time by dispersing a very small amt. of endotoxin in a solvent containing a specific stabilizer. CONSTITUTION: An endotioxin stabilizer containing one or more kind of a substance selected from the group consisting of aminoalcohol, polyhydric alcohol, a nonionic surfactant, polyglycol and a chelating agent as an effective component is used. Concretely, the stabilizer contains aminoalcohol as an effective component and further contains polyhydrlc alcohol and/or polyethylene glycol. Further, the stabilizer contains glycerol or a derivative thereof as an effective component. The stabilizer contains at least one of the chelating agent and the nonionic surfactant.
A biofilm lifestyle is critical for bacterial pathogens to colonize and protect themselves from host immunity and antimicrobial chemicals in plants and animals. The formation and regulation mechanisms of phytobacterial biofilm are still obscure. Here we found that the protein Ralstonia solanacearum resistance to ultraviolet C (RuvC) is highly abundant in biofilm and positively regulates pathogenicity by controlling systemic movement in tomato xylem. RuvC protein accumulates at the later stage of biofilm development and specifically targets Holliday junction (HJ)-like structures to disrupt the biofilm extracellular DNA (eDNA) lattice, thus facilitating biofilm dispersal. Recombinant RuvC protein can resolve extracellular HJ to prevent bacterial biofilm formation. Heterologous expression of R. solanacearum or Xanthomonas oryzae pv. oryzae RuvC with plant secretion signal in tomato or rice confers resistance to bacterial wilt or bacterial blight disease, respectively. Plant chloroplast-localized HJ resolvase monokaryotic chloroplast 1 (MOC1), which shares structural similarity with bacterial RuvC, shows a strong inhibitory effect on bacterial biofilm formation. Relocalization of SlMOC1 to apoplast in tomato roots leads to increased resistance to bacterial wilt. Our novel finding reveals a critical pathogenesis mechanism of R. solanacearum and provides an efficient biotechnology strategy to improve plant resistance to bacterial vascular disease.
In the first interview, scales were applied to the control group patients but planned discharge training was not given. The second interview was carried out 4 weeks later, and after the same scales were reapplied to the control group patients, planned discharge training was given. Therefore, the right of individuals to get education was not prevented.
Micro-K® Extencaps® Capsules and Micro-K® 10 Extencaps® Capsules are oral dosage forms of microencapsulated potassium chloride containing 600 and 750 mg, respectively, of potassium chloride, USP, equivalent to 8 and 10 mEq of potassium, respectively. 

Dispersibility of potassium chloride (KCI) is accomplished by microencapsulation and a dispersing agent. The resultant flow characteristics of the KCI microcapsules and the controlled release of K+ ions by the microcapsular membrane are intended to avoid the possibility that excessive amounts of KCI can be localized at any point on the mucosa of the gastrointestinal tract. 

Each crystal of KCI is microencapsulated by a patented process with an insoluble polymeric coating which functions as a semi-permeable membrane; it allows for the controlled release of potassium and chloride ions over an eight-to ten-hour period. Fluids pass through the membrane and gradually dissolve the potassium chloride within the microcapsules. The resulting potassium chloride solution slowly diffuses outward through the membrane. Micro-K® and Micro-K® 10 are electrolyte replenishers. The chemical name of the active ingredient is potassium chloride and the structural formula is KCI. Potassium chloride, USP, occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste. Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. 

The inactive ingredients are edible ink, ethylcellulose, FD&C Blue No. 2 aluminum lake, FD&C Yellow No. 6, gelatin, magnesium stearate, sodium lauryl sulfate, titanium dioxide. May contain FD&C Red No. 40 and Yellow No. 6 aluminum lakes.
To obtain by laparoscopy a viable uterus for transplantation from a living donor is feasible. The laparoscopic procedure increases safety and provides the benefits of minimally invasive surgery to the grafting technique already described by laparotomy. The objective of the present study is to develop a pilot program in the transplant of a living donor. We include 5 pairs of uterine donor-transplant recipients indicated for sterility by absolute uterine factor due to Mayer Rokitansky Syndrome. Patients will undergo surgery for this transplant and after 6 months of it with correct function of the graft, embryos will be transferred in order to achieve pregnancy. C-section will be performed for delivery. The attempt of two gestations (if there are sufficient cryopreserved embryos for a second gestation) and withdrawing the graft (hysterectomy) and, therefore, immunosuppression is agreed.